Biotech stocks are a hit and miss and if you miss, you lose everything. Exact Sciences (EXAS) bucked the trend. The colon detection kit supplier reported revenue growing 227%. That is not a typo. Cologuard tests grew 150% to 100,000 though costs per test fell 25% to $170. The company forecasts test growing to 470K, up from 415k. EXAS earned -$0.32/share in the first quarter.Nokia Corp. (NOK) jumped ~7% intraday after reporting software sales and mobile flattening. Networking, hurt by IP/Optical, was offset by those other segments. $6/share could be next for NOK. $10 is unlikely but 2018-19 prospects are better. Wait for carriers to sign contracts for 5G builds.Paypal (PYPL) is a darling for value investors. The company reported solid numbers, yet again. Forget Square (SQ) or other payment processing firms. The $0.44 per share earnings on 17.3% Y/Y revenue growth speaks for itself. PYPL raised its guidance to revenue growth of 15-17%. It now expects FY2017 earnings of up to $1.79/share.PYPL is buying back $5 billion in shares.Bonus: Canada’s subprime darling, Home Capital (HMCBF) rebounded after getting an emergency $2 billion. The interest rate for the 1-year term is 20%.